📈 Fed's first cut since 2020: Time to buy the dip? See Tech-focused stock picksUnlock AI Picks

Lyell Immunopharma Inc (LYEL)

NASDAQ
Currency in USD
Disclaimer
1.390
+0.150(+12.10%)
Closed
After Hours
1.380-0.010(-0.719%)
LYEL Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
1.2101.405
52 wk Range
1.0903.256
Prev. Close
1.39
Open
1.28
Day's Range
1.21-1.405
52 wk Range
1.09-3.256
Volume
769,219
Average Vol. (3m)
901,423
1-Year Change
-14.2%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
LYEL Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
3.667
Upside
+163.813%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Lyell Immunopharma Inc Company Profile

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company’s preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Compare LYEL to Peers and Sector

Metrics to compare
LYEL
Peers
Sector
Relationship
P/E Ratio
−1.7x−3.0x−0.6x
PEG Ratio
−1.22−0.050.00
Price / Book
0.6x2.8x2.6x
Price / LTM Sales
6,589.7x8.2x3.1x
Upside (Analyst Target)
222.6%186.8%57.2%
Fair Value Upside
Unlock17.8%7.3%Unlock

People Also Watch

4.180
SEAT
+2.70%
1.100
RLYB
0.00%
0.6590
BNOX
-1.50%
0.943
KRON
-1.05%

FAQ

What Is the Lyell Immunopharma (LYEL) Stock Price Today?

The Lyell Immunopharma stock price today is 1.39

What Stock Exchange Does Lyell Immunopharma Trade On?

Lyell Immunopharma is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Lyell Immunopharma?

The stock symbol for Lyell Immunopharma is "LYEL."

What Is the Lyell Immunopharma Market Cap?

As of today, Lyell Immunopharma market cap is 355.84M.

What is Lyell Immunopharma Earnings Per Share?

The Lyell Immunopharma EPS is -0.83.

What Is the Next Lyell Immunopharma Earnings Date?

Lyell Immunopharma will release its next earnings report on Nov 05, 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.